A phase I/II study of bevacizumab (rhuMAb VEGF [vascular endothelial growth factor]) in combination with OSI-774 [erlotinib] for patients with recurrent or metastatic cancer of the head and neck

Trial Profile

A phase I/II study of bevacizumab (rhuMAb VEGF [vascular endothelial growth factor]) in combination with OSI-774 [erlotinib] for patients with recurrent or metastatic cancer of the head and neck

Completed
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Dec 2012 Primary endpoints added as reported by ClinicalTrials.gov.
    • 23 Mar 2009 Results have been published in Lancet Oncology.
    • 23 Mar 2009 Status changed from active, no longer recruiting to completed as results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top